• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/2/21 1:19:06 PM ET
    $PPD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PPD alert in real time by email
    SC 13G 1 brhc10019641_sc13g.htm SC 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    PPD, Inc.
    (Name of Issuer)

    Common Stock, par value $0.01 per share
    (Titles of Class of Securities)

    69355F102
    (CUSIP Number)

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. 69355F102
    13G
    Page 2 of 7
    1
    NAMES OF REPORTING PERSONS
     
     
    Abu Dhabi Investment Authority (1)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    The Emirate of Abu Dhabi, United Arab Emirates
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    18,899
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    21,453,252
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    15,999
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    21,456,152
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    21,472,151
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.14% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1) Abu Dhabi Investment Authority is the direct owner of 18,899 of the shares of Common Stock represented herein.

    (2) Based on a total of 349,654,449 shares of Common Stock outstanding as of October 26, 2020, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 28, 2020.


    CUSIP No. 69355F102
    13G
    Page 3 of 7
    1
    NAMES OF REPORTING PERSONS
     
     
    Platinum Falcon B 2018 RSC Limited (1)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    -0-
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    21,453,252
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    -0-
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    21,453,252
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    21,453,252
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.14% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1) Platinum Falcon B 2018 RSC Limited (“Platinum Falcon”) is the direct owner of 21,453,252 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the Securities and Exchange Commission, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon.

    (2) Based on a total of 349,654,449 shares of Common Stock outstanding as of October 26, 2020, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 28, 2020.


    Item 1(a).
    Name of Issuer:

    PPD, Inc.
     
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    929 North Front Street, Wilmington,
     
    North Carolina 28401
     
    Item 2(a).
    Name of Person Filing:


    1.
    Abu Dhabi Investment Authority


    2.
    Platinum Falcon B 2018 RSC Limited

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is as follows:


    1.
    211 Corniche Street
    P.O. Box 3600
    Abu Dhabi, United Arab Emirates 3600


    2.
    Level 26, Al Khatem Tower
    Abu Dhabi Global Market Square
    Al Maryah Island, Abu Dhabi
    United Arab Emirates

    Item 2(c).
    Citizenship:


    1.
    Abu Dhabi Investment Authority (ADIA) is a public institution established by the Government of the Emirate of Abu Dhabi in 1976 as an independent investment institution. ADIA is a public institution wholly owned by the Emirate of Abu Dhabi and is subject to its supervision.


    2.
    Platinum Falcon B 2018 RSC Limited is a restricted scope company organized under the laws of the Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates.

    Item 2(d).
    Titles of Classes of Securities:

    Common Stock, $0.01 par value per share
     
    Item 2(e).
    CUSIP Number:

    69355F102

    Page 4 of 7
     

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     
    (a)
    ☐ Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).

     
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     
    (d)
    ☐ Investment company registered under Section 8 of the Investment
    Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    ☐ Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     
    (f)
    ☐ Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     
    (g)
    ☐ Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

     
    (h)
    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (13 U.S.C. 1813).

     
    (i)
    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).

     
    (j)
    ☐ Non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J).

     
    (k)
    ☐ Group in accordance with §240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution: ______________

    Item 4.
    Ownership


    (a)
    Amount Beneficially Owned:

    See responses to Item 9 on each cover page.


    (b)
    Percent of Class:

    See responses to Item 11 on each cover page.


    (c)
    Number of shares as to which such person has:

     

    (i)
    Sole power to vote or to direct the vote:
     
    See responses to Item 5 on each cover page.
     
    Page 5 of 7



    (ii)
    Shared power to vote or to direct the vote:
     
    See responses to Item 6 on each cover page.


    (iii)
    Sole power to dispose or to direct the disposition of:
     
    See responses to Item 7 on each cover page.


    (iv)
    Shared power to dispose or to direct the disposition of:
     
    See responses to Item 8 on each cover page.

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.

    Not Applicable.
     
    Item 9.
    Notice of Dissolution of Group.

    Not Applicable.
     
    Item 10.
    Certification.

    Not applicable.
     
    Page 6 of 7
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: February 2, 2021
     
     
    ABU DHABI INVESTMENT AUTHORITY
       
     
    /s/ Humaid Bin Bishr Almarri
     
     
    By: Humaid Bin Bishr Almarri
     
    Title: Authorized Signatory
       
     
    /s/ Ahmed Ghubash
     
     
    By: Ahmed Ghubash
     
    Title: Authorized Signatory

     
    PLATINUM FALCON B 2018 RSC LIMITED
       
     
    /s/ Humaid Bin Bishr Almarri
     
     
    By: Humaid Bin Bishr Almarri
     
    Title: Authorized Signatory
       
     
    /s/ Ahmed Ghubash
     
     
    By: Ahmed Ghubash
     
    Title: Authorized Signatory

     
    Page 7 of 7

    Get the next $PPD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPD

    DatePrice TargetRatingAnalyst
    8/5/2021$47.50Neutral
    Credit Suisse
    More analyst ratings

    $PPD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

      WALTHAM, Mass., Dec. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (NASDAQ:PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. "We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapi

      12/8/21 8:45:00 AM ET
      $PPD
      $TMO
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Industrial Machinery/Components
      Industrials
    • PPD Named to 'Best Workplaces in Greater China' for Second Consecutive Year

      PPD, Inc. (NASDAQ:PPD) was named one of the "Best Workplaces in Greater China™ 2021" by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in Greater China. This is the second year PPD has received this recognition from Great Place to Work®, a global authority on high-trust, high-performance workplace cultures. "We remain committed to providing a healthy and open work environment for our employees, and this award shows that we continue to be successful in our efforts for yet another year," said D

      12/7/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on PPD with a new price target

      Credit Suisse resumed coverage of PPD with a rating of Neutral and set a new price target of $47.50

      8/5/21 6:25:35 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by JP Morgan with a new price target

      JP Morgan downgraded PPD from Overweight to Neutral and set a new price target of $48.00

      4/28/21 10:25:55 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Jefferies

      Jefferies downgraded PPD from Buy to Hold

      4/20/21 8:11:33 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    SEC Filings

    See more
    • SEC Form 15-12B filed by PPD, Inc.

      15-12B - PPD, Inc. (0001793294) (Filer)

      12/20/21 5:20:22 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PPD, Inc.

      S-8 POS - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:16:02 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:12:04 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Financials

    Live finance-specific insights

    See more
    • PPD Announces Third Quarter 2021 Earnings Conference Call

      PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5

      10/18/21 4:05:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

      CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) f

      11/30/20 6:59:00 AM ET
      $MRNA
      $PPD
      $MCK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Other Pharmaceuticals

    $PPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PPD, Inc.

      SC 13G - PPD, Inc. (0001793294) (Subject)

      12/9/21 5:06:56 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 4:19:09 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 6:11:58 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Leadership Updates

    Live Leadership Updates

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/9/21 5:14:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 5:05:14 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:53:26 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care